Go forward hand in hand to create brilliance
RareStone & HSN Strategic Cooperation Press Conference
October 20th, 2023
On October 18, 2023, RareStone Group (hereinafter referred to as RareStone) and Zhejiang Hesenna Medicine Co., Ltd. (hereinafter referred to as HSN) successfully held a strategic cooperation press conference in Guangzhou, and signed a national general agent contract for Wakix®!
Mr.Xiang Yu, CEO of RareStone, Mr. Xun Zhimeng, vice president and head of Citrine Medicine, Mr. Zhang Shengjie, vice president and head of finance, and Mr. Cao Heng, director of business and supply chain; Ms. Li Shu, Chairman of HSN, Mr. Yan Amin, General Manager, Ms. Liang Jianhua, Deputy General Manager, Ms. Fu Lingxia, Marketing Director, and Mr. Chen Duowen, Project Director, attended the signing ceremony.
At the beginning of the conference, CEO of RareStone, Mr. Xiang Yu and Vice President, Mr. Xun Zhimeng, together with Chairman of HSN, Ms. Li Shu and General Manager, Mr. Yan Amin, injected energy into the project at carefully selected auspicious moments to witness together the glorious moment when RareStone and HSN start their strategic cooperation!
Mr. Xiang Yu, CEO of RareStone, and Ms. Li Shu, Chairman of HSN, signed a strategic cooperation agreement as representatives of both parties. This strategic cooperation announcement marks a new stage of cooperation between the two companies, and will also be an important starting point for HSN to move into the field of rare disease treatment!
After the signing ceremony, the leaders of both parties gave sincere speeches!
Mr. Xiang Yu, CEO of RareStone, expressed the HSN team’s market access, market insights into the field of narcolepsy and WAKIX® products since they contacted HSN in the past three months, as well as the enthusiasm and combat effectiveness of the frontline colleagues for the business have left a deep impression on RareStone! RareStone is full of confidence in the strategic cooperation and wishes the cooperation between the two sides a complete success!
.
Ms. Li Shu, Chairman of HSN, delivered a speech. The two companies quickly reached consensus on cooperation, which should give the credit to the good products of RareStone Group and also to the trust of RareStone Group in HSN. Due to its originality and excellent efficacy, WAKIX® has become the most outstanding drug for the treatment of narcolepsy! The cooperation between the two companies comes at the right time. All HSN employees have attached great importance to it from top to bottom, and with the help of the national sales network, they will give full play to the professional, efficient and pragmatic style of the marketing team to cooperate with RareStone, complement each other’s advantages and achieve win-win cooperation so as to effectively promote market planning and layout and become a trustworthy partner for each other!
The strategic cooperation between RareStone and HSN is a cooperation between powerful enterprises for common development. Both parties will jointly draw a development blueprint to achieve a new leap in strategic development!
Attachment 1: Narcolepsy
Chinese Guidelines for the Diagnosis and Treatment of Narcolepsy (2022 Edition) pointed out that the concept of narcolepsy was first proposed by the French doctor Gélineau in 1880. Clinically, it is characterized by excessive daytime sleepiness (EDS), cataplexy, and nocturnal sleep disturbance. Narcolepsy can occur in childhood, and the average delay from onset to diagnosis is 8 to 22 years. The course of the disease spans critical periods of education and personal development. The clinical symptoms severely affect patients’ learning, life and social functioning, leading to difficulties in receiving normal education, employment, reduced income, and missed opportunities for career advancement.
Attachment 2: Pitolisant (Wakix®)
Pitolisant is a selective H3 receptor antagonist/inverse agonist that increases the synthesis and release of the wakefulness-promoting neurotransmitter histamine in the brain by enhancing histaminergic neuron activity, thereby improving wakefulness and alertness in patients. Pitolisant was granted breakthrough therapy designation by the FDA in October 2018.
On June 30, 2023, the National Medical Products Administration (NMPA) of China officially approved Wakix® (Pitolisant Hydrochloride Tablets) for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.
Attachment 3: Expert Consensus on the Clinical Diagnosis and Treatment of Excessive Daytime Sleepiness
– National Medical Journal of China, Vol. 103, No. 15, 2023-4-18
Excessive daytime sleepiness (EDS) refers to the inability to stay awake and alert for a period of time during which one needs to stay awake, with uncontrollable sleep needs or even involuntarily falling asleep, which can be accompanied by attention and memory impairment.
Currently, the first-line drug for the treatment of EDS based on current evidence from evidence-based medicine is Pitolisant.
